Be a Smart Investor
Monday, April 27, 2020
Axsome Therapeutics (AXSM) Advances To Cross $100-Mark
Axsome Therapeutics Inc.'s (AXSM) phase II/III trial of investigational drug AXS-05 in Alzheimer's disease agitation has met the primary endpoint.
from RTT - Biotech https://ift.tt/2KC5SgP
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment